JMP Securities Reiterates a Buy Rating on Steris Corp.

By Ryan Adsit

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Steris Corp. (NYSE: STE). The company’s shares opened today at $64.31.

According to, Turkaly is a 5-star analyst with an average return of 14.4% and a 55.9% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Orasure Technologies.

Steris Corp. has an analyst consensus of Moderate Buy.

The company has a one year high of $78.77 and a one year low of $61.38. Currently, Steris Corp. has an average volume of 482.9K.

STERIS Plc engages in the manufacture of surgical and other medical supplies. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences and Applied Sterilization Technologies. The Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. The Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. The Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. The Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The company was founded on October 9, 2014 and is headquartered in Leicester, United Kingdom.